Chromogranin A: Its clinical value as marker of neuroendocrine rumours

European Journal of Clinical Investigation

Volumn 28, Issue 6, 1998, Pages 431-440

  Nobels, F R E ^a,c   Kwekkeboom, D J ^a   Bouillon, R ^b   Lamberts, S W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c OLV HOSPITAL   (Belgium)

Author keywords

Chromogranins; Endocrine diseases; Tumour markers

Indexed keywords

CATECHOLAMINE; CHROMOGRANIN A; SECRETORY PROTEIN; SEROTONIN; TUMOR MARKER;

CARCINOID; COLORECTAL CARCINOMA; HUMAN; IMMUNOSCINTIGRAPHY; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PANCREAS ADENOCARCINOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; TUMOR VOLUME;

CHROMOGRANIN A; CHROMOGRANINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031842127     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00305.x     Document Type: Review

References (97)

1. Wiedenmann B, Huttner WB. Synaptophysin and chromogranins/secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol 1989; 58: 95-121.
2. Deftos LJ. Chromogranin A. its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocrine Rev 1991; 12: 181-7.
3. Winkler H, Fischer-Colbrie R. The chromogranins A and B. the first 25 years and future perspectives. Neuroscience 1992; 49: 497-528.
4. Rosa P, Gerdes HH. The granin family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest 1994; 17: 207-25.
5. Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995; 58: 65-88.
6. Eiden LE, Huttner WE, Mallet J, O'Connor DT, Winkler H, Zanini A. A nomenclature proposal for the chromogranin/ secretogranin proteins. Neuroscience 1987; 21: 1019-21.
7. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin from the adrenal gland after splanchnic stimulation. Nature 1967; 215: 58-9.
8. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT. Structure and function of the chromogranin A gene. Clues to evolution and tissue specific expression. J Biol Chem 1991; 266: 13130-4.
9. Nolan EM, Cheung TC, Burton DW, Deftos LJ. Identification and characterization of a neuroendocrine-specific 5′-regulatory region of the human chromogranin A gene. Endocrinology 1995; 136: 5632-42.
10. Benedum UM, Baeuerle PA, Konecki DS, et al. The primary structure of bovine chromogranin A. EMBO J 1986; 5: 1495-502.
11. Helman LJ, Ahn TG, Levine MA, et al. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem 1988; 263: 11559-63.
12. Grimes M, Iacangelo A, Eiden LE, Godfrey B, Herber E. Chromogranin A: the primary structure deduced from cDNA clones reveals the presence of pairs of basic amino acids. Ann NY Acad Sci 1987; 493: 351-78.
13. Gorr SU, Dean WL, Radley TL, Cohn DV. Calcium-binding and aggregation properties of parathyroid secretory protein-I (chromogranin A). Bone Mineral 1988; 4: 17-25.
14. 2+-induced conformational change and aggregation of chromogranin A. J Biol Chem 1990; 265: 14414-21.
15. Benedum UM, Lamouroux A, Konecki DS, et al. The primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. EMBO J 1987; 6: 1203-11.
16. Chanat E, Weiss U, Huttner WB, Tooze SA. Reduction of the disulfide bond of chromogranin B (secretogranin I) in the trans-Golgi network causes its missorting to the constitutive secretory pathways. EMBO J 1993; 12: 2159-68.
17. Peterson JB, Nelson DL, Ling E, Hogue-Angeletti R. Chromogranin A-like proteins in the secretory granules of a protozoan, Paramecium tetraurelia. J Biol Chem 1987; 262: 264-7.
18. Iacangelo A, Fischer-Colbrie R, Koller KJ, Brownstein MJ, Eiden LE. The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin can serve as the precursor for the biologically active hormone pancreastatin. Endocrinology 1988; 122: 2339-41.
19. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476-8.
20. Ishizuka J, Asada I, Poston GJ, et al. Effect of pancreastatin on pancreatic endocrine and exocrine secretion. Pancreas 1989; 4: 277-81.
21. Fasciotto BH, Gorr SU, DeFranco DJ, Levine MA, Cohn DV. Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture. Endocrinology 1989; 125: 1617-22.
22. Lewis JJ, Goldering JR, Asher VA, Modlin IM. Pancreastatin: a novel peptide inhibitor of parietal cell signal transduction. Biochem Biophys Res Commun 1989; 163: 667-73.
23. Schmidt WE, Siegel EG, Lamberts R, Gallwitz B, Creutzfeldt W. Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues. Endocrinology 1988; 123: 1395-404.
24. Sekiya K, Ghatei MA, Minamino N, Bretherton-Watt D, Matsuo H, Bloom SR. Isolation of human pancreastatin fragment containing the active sequence form a glucagonoma. FEBS Lett 1988; 228: 153-6.
25. 2+-dependent endopeptidase and carboxypeptidase. Biochem J 1987; 244: 457-64.
26. Drees BM, Hamilton JW. Processing of chromogranin A by bovine parathyroid secretory granules: production and secretion of N-terminal fragments. Endocrinology 1994; 134: 2057-63.
27. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992; 41: 9-18.
28. Russell J, Gee P, Liu SM, Angeletti RH. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 1994; 135: 337-42.
29. Fasciotto BH, Trauss CA, Greeley GH, Cohn DV. Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 1993; 133: 461-6.
30. Deftos LJ, Hogue-Angeletti R, Chalberg C, Tu S. A chromogranin A-derived peptide differentially regulates the secretion of calcitonin gene products. J Bone Miner Res 1990; 5: 989-91.
31. Deftos LJ, Hogue-Angeletti R, Chalberg C, Tu S. PTHrP secretion is stimulated by calcitonin and inhibited by chromogranin A peptides. Endocrinology 1989; 125: 563-5.
32. Galindo E, Rill A, Bader MF, Aunis D. Chromostarin, a 20-amino acid chromogranin A-derived peptide, inhibits chromaffin cell secretion. Proc Natl Acad Sci USA 1991; 88: 1426-30.
33. Galindo E, Mendez M, Calvo S, et al. Chromostatin receptors control calcium channel activity in adrenal chromaffin cells. J Biol Chem 1992; 267: 407-12.
34. Galindo E, Zwiller J, Bader MF, Aunis D. Correction. Proc Natl Acad Sci USA 1991; 88: 1426-30.
35. Laslop A, Fischer-Colbrie R, Kirschke H, Hogue-Angeletti R, Winkler H. Chromogranin A-processing proteinases in purified chromaffin granules: contaminants or endogenous enzymes Biochem Biophys Acta 1990; 1033: 65-72.
36. Eskeland NL, Zhou A, Dinh TQ, Wu H, Parmer RJ, Mains RE, O'Connor DT. Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest 1996; 98: 148-56.
37. Christie DL, Batchelor DC, Plamer DJ. Identification of kex2-related proteases in chromaffin granules by partial amino acid sequence analysis. J Biol Chem 1991; 266: 679-93.
38. Deftos LJ, Gazdar AF, Hogue-Angeletti R, Mullen PS, Burton DW. Distinct patterns of chromogranin A-related species can be demonstrated in endocrine cells. Bone Mineral 1990; 9: 169-78.
39. Benjannet S, Leduc R, Adrouche N, et al. Chromogranin B (secretogranin I), a putative precursor of two novel pituitary peptides through processing at paired basic residues. FEBS Lett 1987; 224: 142-8.
40. Sekiya K, Ghatei MA, Salahuddin MJ, et al. Production of GAWK (chromogranin-B 420-493) -like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest 1989; 83: 1834-42.
41. Vaudry H, Conlon JM. Identification of a peptide arising from the specific post-translational processing of secretogranin II. FEBS Lett 1991; 284: 31-3.
42. Seidah NG, Hendy GN, Hamelin J, et al. Chromogranin A can act as a reversible processing enzyme inhibitor. Evidence from the inhibition of the IRCM-serine protease 1 cleavage of pro-enkephalin and ACTH at pairs of basic amino acids. FEBS Lett 1987; 211: 144-50.
43. Pimplikar SW, Huttner WB. Chromogranin B (secretogranin I), a secretory protein of the regulated pathway, is also present in a tightly membrane-associated form in PC12 cells. J Biol Chem 1992; 267: 4110-8.
44. Tooze SA, Huttner WB. Cell-free protein sorting to the regulated and constitutive secretory pathways. Cell 1990; 60: 837-47.
45. Chanat E, Huttner WB. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991; 115: 1505-19.
46. Kelly RB. Pathways of protein secretion in eukaryotes. Science 1985; 230: 25-32.
47. O'Connor DT, Burton D, Deftos LJ. Immunoreactive chromogranin A in diverse polypeptide hormone producing tumors and normal endocrine tissues. J Clin Endocrinol Metab 1983; 57: 1084-6.
48. Weiler R, Fischer-Colbrie R, Schmid KW, et al. Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol 1988; 12: 877-84.
49. Lloyd RV, Wilson BS. Specific endocrine tissue marker denned by a monoclonal antibody. Science 1983; 222: 628-30.
50. DeStephano DB, Lloyd RV, Pike AM, Wilson BS. Pituitary adenomas: an immunohistochemical study of hormone production and chromogranin localization. Am J Pathol 1984; 116: 464-72.
51. Lloyd RV, Iacangelo A, Eiden LE, Cano M, Jin L, Grimes M. Chromogranin A and B messenger ribonucleic acids in pituitary and other normal and neoplastic human endocrine tissues. Lab Invest 1989; 60: 548-56.
52. Nobels FRE, Kwekkeboom DJ, Coopmans W, Hoekstra R, Bouillon R, Lamberts SWJ. A comparison between the diagnostic value of the measurement of gonadotropins, α-subunits and chromogranin A and their response to TRH in clinically nonfunctioning, α-subunit secreting and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 1993; 77: 784-9.
53. Gould VE, Lee I, Warren WH. Immunohistochemical evaluation of neuroendocrine cells and neoplasms of the lung. Pathol Res Pract 1988; 183: 200-13.
54. Schmid KW, Hittmair A, Ladurner D, Sandbichler P, Gasser R, Totsch M. Chromogranin A and B in parathyroid tissue of cases of primary hyperparathyroidism: an immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1991; 418: 295-9.
55. Belaiche J, Delwaide J, Vivario M, Gast P, Louis E, Boniver J. Fundic argyrophil cell hyperplasia in atrophic gastritis: a search for a sensitive diagnostic method. Acta Gastroenterol 1993; 56: 11-7.
56. Lloyd RV, Cano M, Rosa P, Hille A, Huttner WB. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. Am J Pathol 1988; 130: 296-304.
57. Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones/ prohormones and relationship with the argyrophil component of secretory granules. Histochemistry 1986; 85: 19-28.
58. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumors. Br J Cancer 1991; 64: 333-8.
59. Scopsi L, Andreola S, Pilotti S, et al. Argyrophylia and granin (chromogranin/secretogranin) expression in female breast carcinomas. Their relationship to survival and other disease parameters. Am J Surg Pathol 1992; 16: 561-76.
60. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70: 254-68.
61. De Bruine AP, Wiggers T, Beek C, et al. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 1993; 54: 765-71.
62. Pour PM, Permert J, Mogaki M, Fujii H, Kazakoff K. Endocrine aspects of exocrine cancer of the pancreas. Their patterns and suggested biologic significance. Am J Clin Pathol 1993; 100: 223-30.
63. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984; 311: 764-70.
64. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A. in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989; 35: 1631-7.
65. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ. Elevated serum chromogranin A concentrations in small cell lung carcinoma. Ann Intern Med 1986; 105: 698-700.
66. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145-51.
67. Cryer PE, Wortsman J, Shah SD, Nowak RM, Deftos LJ. Plasma chromogranin A as marker of sympathochromaffin activity in humans. Am J Physiol 1991; 260: E243-6.
68. Elias AN, Wilson AF, Pandian MR, Kayaleh R. Chromogranin A concentrations in plasma of physically active men after acute exercise. Clin Chem 1992; 38: 2348-9.
69. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HPH, O'Connor DT. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab 1990; 71: 360-9.
70. Stridsberg M, Öberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
71. Nobels FRE, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-8.
72. Hsiao RJ, Neumann HPH, Parmer RJ, Barbosa JA, O'Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 1990; 88: 607-13.
73. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine 1991; 70: 33-45.
74. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993; 32: 161-5.
75. D'Adda T, Corleto V, Pilato FP, Baggi MT, Robutti F, Delle Fave G. Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Gastroenterology 1990; 99: 17-26.
76. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649-53.
77. Stabile BE, Howard TJ, Passaro E, O'Connor DT. Source of plasma chromogranin-A elevation in gastrinoma patients. Arch Surg 1990; 125: 451-3.
78. Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine rumors. N Engl J Med 1989; 320: 444-7.
79. Schürmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg 1992; 16: 697-702.
80. Deftos LJ, O'Connor DT, Wilson CB, Fitzgerald PA. Human pituitary tumors secrete chromogranin-A. J Clin Endocrinol Metab 1989; 68: 869-72.
81. Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for pheochromocytoma. Eur J Endocrinol 1997; 136: 29.
82. Nobels FRE, de Herder WW, Kwekkeboom DJ, et al. Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur J Endocrinol 1994; 131: 589-93.
83. Moattari AR, Deftos LJ, Vinik AI. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. J Clin Endocrinol Metab 1989; 69: 902-5.
84. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991; 146: 358-61.
85. Syversen U, Halvorsen T, Marvik R, Waldum HL. Neuroendocrine differentiation in colorectal carcinomas. Eur J Gastroenterol Hepatol 1995; 7: 667-74.
86. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155: 1340-3.
87. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett AT, Abrahamsson PA. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996; 48: 58-62.
88. Aprikian AG, Cordon-Cardo C, Fair WR, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994; 151: 914-9.
89. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993; 71: 3952-65.
90. Hamada Y, Oishi A, Shoji T, et al. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 1992; 69: 2641-6.
91. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158: 171-4.
92. Eriksson B, Arnberg H, Öberg K, et al. A polyclonal antiserum against chromogranin A and B - a new sensitive marker for neuroendocrine tumours. Acta Endocrinol 1990; 122: 145-55.
93. Magnani P, Paganelli G, Siccardi AG, et al. Combined use of 111 In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin A monoclonal antibody in the diagnosis of pituitary adenomas. Cell Biophys 1994; 24-25P: 307-13.
94. Colombo P, Siccardi AG, Paganelli G, et al. Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region. Eur J Endocrinol; 1996: 135: 216-21.
95. Siccardi AG, Paganelli G, Pontiroli AE, et al. In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting. Eur J Nucl Med 1996; 23: 1455-9.
96. Magnani P, Paganelli G, Songini C, et al. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer 1996; 74: 825-31.
97. Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 1991; 12: 450-82.